Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Leukemia

Leukemia

582

Pipeline Programs↗

1.1K

Active Trials↗

295

Companies Involved↗

Leukemia is a highly competitive landscape with 582 programs across 295 companies. The most active players are Essen Biotech, Guangzhou Ruixin Biotechnological Co., LTD. 91 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

100/100

Pipeline Velocity

100/100

Mech. Concentration

4/100

Completion Rate

70/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Essen Biotech

1 program

Guangzhou Ruixin Biotechnological Co., LTD

1 program

Pipeline

Programs by Phase

Preclinical122

Furosemide

Validus Pharmaceuticals

Dexamethasone Sodium Phosphate

Quince Therapeutics S.p.A.

Methylprednisolone Sodium Succinate

Massachusetts Eye and Ear Infirmary

Interferon Alpha

Ainos, Inc. (f/k/a Amarillo Biosciences Inc.

CD7 CAR T-Cells

iCell Gene Therapeutics

Phase 1172

Tocilizumab

Celltrion

JY231

Shenzhen Genocury Biotech Co., Ltd.

Zeprumetostat

Sun Yat-sen University

Gene-Modified T Cells Targeted

Memorial Sloan Kettering Cancer Center

Karonudib

Thomas Helleday Foundation

Phase 2197

Pegfilgrastim

Amgen

Tisagenlecleucel

Novartis

Intravenous Immunoglobulin

University of Alabama at Birmingham

Mononuclear Cells

National University of Malaysia

Tafasitamab

Incyte

Phase 391

Doxorubicin Hydrochloride

Pfizer

Mesna

Baxter Healthcare Corporation

Thiotepa

Jazz Pharmaceuticals

Vorinostat

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Busulfan

Akero Therapeutics

Approved

No programs

Analysis

Modality Breakdown

71%

Small molecule

346 of 487 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 487 classified programs, each share of the total. Modality classified for 94% of 582 pipeline programs.

Analysis

Trial Status

3,855

clinical trials

Completed1,685 · 44%

Recruiting604 · 16%

Terminated520 · 13%

Unknown status349 · 9%

Active, not recruiting332 · 9%

Withdrawn168 · 4%

Other197 · 5%

Clinical Trials

Trial Activity

3855 trials

A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of RVU120 in Combination With Venetoclax in Participants With Acute Myeloid Leukemia Who Failed Prior Therapy With Ventoclax and a Hypomethylating Agent

Recruiting·RRyvu Therapeutics SA·Phase 2·NCT06191263·98 enrolled

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT06284486·8 enrolled

Phase 1 Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06769490·44 enrolled

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06561074·22 enrolled

A Prospective, Single-Arm, Single-Center, Phase II Study Evaluating the Safety and Efficacy of CM336 in Combination With Isatuximab, Lenalidomide, and Bortezomib in Newly Diagnosed Primary Plasma Cell Leukemia

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07652905·24 enrolled

A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults With Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Substudy

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT06317649·147 enrolled

A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia

Recruiting·QQuetzal Therapeutics·Phase 3·NCT07504458·150 enrolled

A Measurable Residual Disease (MRD) Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients With Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH SubStudy

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05554393·153 enrolled

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06817720·50 enrolled

A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT00801489·270 enrolled

A Randomized Phase II Trial of ASTX727 and Venetoclax Compared With ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults With IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT06672146·93 enrolled

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05564390·2,000 enrolled

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Therapy

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT03630991·58 enrolled

A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who Are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH SubStudy

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05554406·335 enrolled

A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)

Recruiting·NNurix Therapeutics, Inc.·Phase 2·NCT07221500·100 enrolled

Page 1 of 257

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)